Page 44 - Nasdaq Regn News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA® HD demonstrated clinically equivalent vision gains to EYLEA (aflibercept) Injection...

Truist Financial reissued their buy rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) in a research note released on Wednesday morning, Benzinga reports. The brokerage currently has a $1,045.00 target price on the biopharmaceutical company’s stock. REGN has been the topic of a number of other research reports. Canaccord Genuity Group lowered shares […]

StockNews.com lowered shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) from a strong-buy rating to a buy rating in a research report sent to investors on Saturday morning. Several other analysts also recently commented on the stock. Morgan Stanley raised their price objective on shares of Regeneron Pharmaceuticals from $897.00 to $912.00 and gave the […]

Tredje AP fonden increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 74.9% during the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 48,710 shares of the biopharmaceutical company’s stock after purchasing an additional 20,861 shares during the period. Tredje […]

Manchester Capital Management LLC grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 740.0% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 42 shares of the biopharmaceutical company’s stock after buying an additional 37 shares during the period. Manchester […]